Wakunaga Pharmaceutical Of Japan To Enter Indian Market
This article was originally published in PharmAsia News
Osaka-based Wakunaga Pharmaceutical announced plans to enter the Indian market within the year. The company plans to market over-the-counter drug Kyoleopin and supplements through local Indian wholesalers. Wakunaga's move is to seize upon India's economic development and demand for health products; the company expects to reach ¥100 million in sales during the first year. Wakunaga also plans to enter the Brazilian market, and over the long term, Wakunaga hopes to expand shares in the European market. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.